Secondary efficacy endpoints for the modified intent-to-treat population. حسب Rahsan Erdem (11726357)

الموضوعات:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. حسب Rahsan Erdem (11726357)

الموضوعات:

Source data for Fig 1. حسب Rahsan Erdem (11726357)

الموضوعات:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. حسب Rahsan Erdem (11726357)

الموضوعات:

Source data for S1 and S2 Figs. حسب Rahsan Erdem (11726357)

الموضوعات:

Source data for Fig 2. حسب Rahsan Erdem (11726357)

الموضوعات:

Consolidated Standards for Reporting of Trials flow diagram. حسب Rahsan Erdem (11726357)

الموضوعات:

iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. حسب Rahsan Erdem (11726357)

الموضوعات:

Source data for Fig 3. حسب Rahsan Erdem (11726357)

الموضوعات:

Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate. حسب Rahsan Erdem (11726357)

الموضوعات:

Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. حسب Rahsan Erdem (11726357)

الموضوعات:

Diarrheal disease severity by treatment group for the modified intent-to-treat population. حسب Rahsan Erdem (11726357)

الموضوعات:

Frontier analysis of injuries’ burden caused by fire, heat, and hot substances from 1990 to 2021. حسب Shi Huang (125861)

الموضوعات:

Diagram of the mechanism by which PFAS causes a decrease in constipation. حسب Yifan Zhao (659636)

The burden of injuries caused by fire, heat and hot substances in female and male across 22 GBD regions. حسب Shi Huang (125861)

الموضوعات:

Graph of successive trends in the burden of injury caused by fire, heat and hot substances between 1990 and 2021. حسب Shi Huang (125861)

الموضوعات:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

Frontier Analysis: Countries with high potential for improvement in the burden of injuries caused by fire, heat, and hot substances in 2021. حسب Shi Huang (125861)

الموضوعات: